Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series

Critical Care

Dian Fu¹  Jiqiu Wen¹  Wei Li²  Wu Zhong²  Ruiyuan Cao²  Lei Zhao² 

[1] National Clinical and Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, 210002, Nanjing, China;Wuhan Huoshenshan Hospital, 430100, Wuhan, China;National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, 100850, Beijing, China;

关键词: Favipiravir;    SARS-CoV-2;    COVID-19;    viral RNA persistence;   

DOI  :  10.1186/s13054-020-03288-5

来源: Springer

【 授权许可】

CC BY